Luteolin sensitizes human liver cancer cells to TRAIL‑induced apoptosis via autophagy and JNK‑mediated death receptor 5 upregulation

  • Authors:
    • Uddin Md. Nazim
    • Sang‑Youel Park
  • View Affiliations

  • Published online on: November 14, 2018     https://doi.org/10.3892/ijo.2018.4633
  • Pages: 665-672
Metrics: HTML 0 views | PDF 0 views     Cited By (CrossRef): 0 citations

Abstract

The tumor necrosis factor‑related apoptosis‑inducing ligand (TRAIL) is a dynamic cytokine that initiates the apoptosis of cancer cells, but exhibits little or no toxicity in normal cells. Luteolin is a flavonoid compound frequently used in the treatment of cancer. In the current study, we demonstrate that treatment with luteolin and TRAIL exerts a synergistic effect and the mechanisms on TRAIL‑resistant Huh7 cells. The results demonstrated that luteolin induced an autophagic flux in human liver cancer cells. The attenuation of the autophagic flux by applying the specific inhibitor of autophagy, chloroquine, significantly suppressed DR5 expression. Treatment with genetically modified autophagy‑related 5 siRNA abrogated the luteolin‑mediated sensitizing effect of TRAIL. Furthermore, pre‑treatment with the c‑Jun N‑terminal kinase (JNK) inhibitor, SP600125, significantly attenuated the luteolin‑induced upregulation of DR5 expression, thereby suggesting that JNK activation promotes DR5 expression. Our findings also revealed that Akt phosphorylation was required for TRAIL sensitization. On the whole, the findings of this study indicated that luteolin effectively enhanced TRAIL‑initiated apoptosis, and that these effects were likely to be mediated by autophagy and JNK‑mediated DR5 expression.

References

1 

El-Serag HB and Rudolph KL: Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis. Gastroenterology. 132:2557–2576. 2007. View Article : Google Scholar : PubMed/NCBI

2 

Sherman M: Epidemiology of hepatocellular carcinoma. Oncology. 78(Suppl 1): 7–10. 2010. View Article : Google Scholar : PubMed/NCBI

3 

Balogh J, Victor D III, Asham EH, Burroughs SG, Boktour M, Saharia A, Li X, Ghobrial RM and Monsour HP Jr: Hepatocellular carcinoma: A review. J Hepatocell Carcinoma. 3:41–53. 2016. View Article : Google Scholar : PubMed/NCBI

4 

Arii S: Molecularly targeted therapy for hepatocellular carcinoma from the basic and clinical aspects. Int J Clin Oncol. 15:2342010. View Article : Google Scholar : PubMed/NCBI

5 

Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, Sherman M, Schwartz M, Lotze M, Talwalkar J, et al Panel of Experts in HCC-Design Clinical Trials: Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst. 100:698–711. 2008. View Article : Google Scholar : PubMed/NCBI

6 

Wang S: The promise of cancer therapeutics targeting the TNF-related apoptosis-inducing ligand and TRAIL receptor pathway. Oncogene. 27:6207–6215. 2008. View Article : Google Scholar : PubMed/NCBI

7 

Mahmood Z and Shukla Y: Death receptors: Targets for cancer therapy. Exp Cell Res. 316:887–899. 2010. View Article : Google Scholar

8 

Allen JE and El-Deiry WS: Regulation of the human TRAIL gene. Cancer Biol Ther. 13:1143–1151. 2012. View Article : Google Scholar : PubMed/NCBI

9 

Micheau O, Shirley S and Dufour F: Death receptors as targets in cancer. Br J Pharmacol. 169:1723–1744. 2013. View Article : Google Scholar : PubMed/NCBI

10 

Chen CY, Yiin SJ, Hsu JL, Wang WC, Lin SC and Chern CL: Isoobtusilactone A sensitizes human hepatoma Hep G2 cells to TRAIL-induced apoptosis via ROS and CHOP-mediated up-regulation of DR5. J Agric Food Chem. 60:3533–3539. 2012. View Article : Google Scholar : PubMed/NCBI

11 

Pan G, O’Rourke K, Chinnaiyan AM, Gentz R, Ebner R, Ni J and Dixit VM: The receptor for the cytotoxic ligand TRAIL. Science. 276:111–113. 1997. View Article : Google Scholar : PubMed/NCBI

12 

Walczak H, Degli-Esposti MA, Johnson RS, Smolak PJ, Waugh JY, Boiani N, Timour MS, Gerhart MJ, Schooley KA, Smith CA, et al: TRAIL-R2: A novel apoptosis-mediating receptor for TRAIL. EMBO J. 16:5386–5397. 1997. View Article : Google Scholar : PubMed/NCBI

13 

Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, Blackie C, Chang L, McMurtrey AE, Hebert A, et al: Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest. 104:155–162. 1999. View Article : Google Scholar : PubMed/NCBI

14 

Ashokkumar P and Sudhandiran G: Protective role of luteolin on the status of lipid peroxidation and antioxidant defense against azoxymethane-induced experimental colon carcinogenesis. Biomed Pharmacother. 62:590–597. 2008. View Article : Google Scholar : PubMed/NCBI

15 

Nishitani Y, Yamamoto K, Yoshida M, Azuma T, Kanazawa K, Hashimoto T and Mizuno M: Intestinal anti-inflammatory activity of luteolin: Role of the aglycone in NF-κB inactivation in macrophages co-cultured with intestinal epithelial cells. Biofactors. 39:522–533. 2013. View Article : Google Scholar : PubMed/NCBI

16 

Ashokkumar P and Sudhandiran G: Luteolin inhibits cell proliferation during Azoxymethane-induced experimental colon carcinogenesis via Wnt/β-catenin pathway. Invest New Drugs. 29:273–284. 2011. View Article : Google Scholar

17 

Huang X, Dai S, Dai J, Xiao Y, Bai Y, Chen B and Zhou M: Luteolin decreases invasiveness, deactivates STAT3 signaling, and reverses interleukin-6 induced epithelial-mesenchymal transition and matrix metalloproteinase secretion of pancreatic cancer cells. OncoTargets Ther. 8:2989–3001. 2015. View Article : Google Scholar

18 

Han K, Meng W, Zhang JJ, Zhou Y, Wang YL, Su Y, Lin SC, Gan ZH, Sun YN and Min DL: Luteolin inhibited proliferation and induced apoptosis of prostate cancer cells through miR-301. OncoTargets Ther. 9:3085–3094. 2016. View Article : Google Scholar

19 

Naso LG, Badiola I, Marquez Clavijo J, Valcarcel M, Salado C, Ferrer EG and Williams PAM: Inhibition of the metastatic progression of breast and colorectal cancer in vitro and in vivo in murine model by the oxidovanadium(IV) complex with luteolin. Bioorg Med Chem. 24:6004–6011. 2016. View Article : Google Scholar : PubMed/NCBI

20 

Dia VP and Pangloli P: Epithelial-to-Mesenchymal Transition in Paclitaxel-Resistant Ovarian Cancer Cells Is Downregulated by Luteolin. J Cell Physiol. 232:391–401. 2017. View Article : Google Scholar

21 

Youdim KA, Qaiser MZ, Begley DJ, Rice-Evans CA and Abbott NJ: Flavonoid permeability across an in situ model of the blood-brain barrier. Free Radic Biol Med. 36:592–604. 2004. View Article : Google Scholar : PubMed/NCBI

22 

Jang S, Kelley KW and Johnson RW: Luteolin reduces IL-6 production in microglia by inhibiting JNK phosphorylation and activation of AP-1. Proc Natl Acad Sci USA. 105:7534–7539. 2008. View Article : Google Scholar : PubMed/NCBI

23 

Cao Z, Zhang H, Cai X, Fang W, Chai D, Wen Y, Chen H, Chu F and Zhang Y: Luteolin promotes cell apoptosis by inducing autophagy in hepatocellular carcinoma. Cell Physiol Biochem. 43:1803–1812. 2017. View Article : Google Scholar : PubMed/NCBI

24 

Levine B and Klionsky DJ: Development by self-digestion: Molecular mechanisms and biological functions of autophagy. Dev Cell. 6:463–477. 2004. View Article : Google Scholar : PubMed/NCBI

25 

El-Khattouti A, Selimovic D, Haikel Y and Hassan M: Crosstalk between apoptosis and autophagy: Molecular mechanisms and therapeutic strategies in cancer. J Cell Death. 6:37–55. 2013. View Article : Google Scholar : PubMed/NCBI

26 

Liang C: Negative regulation of autophagy. Cell Death Differ. 17:1807–1815. 2010. View Article : Google Scholar : PubMed/NCBI

27 

Giampietri C, Petrungaro S, Padula F, D’Alessio A, Marini ES, Facchiano A, Filippini A and Ziparo E: Autophagy modulators sensitize prostate epithelial cancer cell lines to TNF-alpha-dependent apoptosis. Apoptosis. 17:1210–1222. 2012. View Article : Google Scholar : PubMed/NCBI

28 

Lorenzi PL, Claerhout S, Mills GB and Weinstein JN: A curated census of autophagy-modulating proteins and small molecules: Candidate targets for cancer therapy. Autophagy. 10:1316–1326. 2014. View Article : Google Scholar : PubMed/NCBI

29 

Yao D, Wang P, Zhang J, Fu L, Ouyang L and Wang J: Deconvoluting the relationships between autophagy and metastasis for potential cancer therapy. Apoptosis. 21:683–698. 2016. View Article : Google Scholar : PubMed/NCBI

30 

Kabeya Y, Mizushima N, Ueno T, Yamamoto A, Kirisako T, Noda T, Kominami E, Ohsumi Y and Yoshimori T: LC3, a mammalian homologue of yeast Apg8p, is localized in autopha-gosome membranes after processing. EMBO J. 19:5720–5728. 2000. View Article : Google Scholar : PubMed/NCBI

31 

Tanida I, Minematsu-Ikeguchi N, Ueno T and Kominami E: Lysosomal turnover, but not a cellular level, of endogenous LC3 is a marker for autophagy. Autophagy. 1:84–91. 2005. View Article : Google Scholar

32 

Nazim UM, Jeong JK and Park SY: Ophiopogonin B sensitizes TRAIL-induced apoptosis through activation of autophagy flux and downregulates cellular FLICE-like inhibitory protein. Oncotarget. 9:4161–4172. 2017.

33 

Kelley SK and Ashkenazi A: Targeting death receptors in cancer with Apo2L/TRAIL. Curr Opin Pharmacol. 4:333–339. 2004. View Article : Google Scholar : PubMed/NCBI

34 

Volkmann X, Fischer U, Bahr MJ, Ott M, Lehner F, Macfarlane M, Cohen GM, Manns MP, Schulze-Osthoff K and Bantel H: Increased hepatotoxicity of tumor necrosis factor-related apoptosis-inducing ligand in diseased human liver. Hepatology. 46:1498–1508. 2007. View Article : Google Scholar : PubMed/NCBI

35 

Yee SB, Choi HJ, Chung SW, Park DH, Sung B, Chung HY and Kim ND: Growth inhibition of luteolin on HepG2 cells is induced via p53 and Fas/Fas-ligand besides the TGF-β pathway. Int J Oncol. 47:747–754. 2015. View Article : Google Scholar : PubMed/NCBI

36 

Park SH, Ham S, Kwon TH, Kim MS, Lee DH, Kang JW, Oh SR and Yoon DY: Luteolin induces cell cycle arrest and apoptosis through extrinsic and intrinsic signaling pathways in MCF-7 breast cancer cells. J Environ Pathol Toxicol Oncol. 33:219–231. 2014. View Article : Google Scholar : PubMed/NCBI

37 

Sun DW, Zhang HD, Mao L, Mao CF, Chen W, Cui M, Ma R, Cao HX, Jing CW and Wang Z: Luteolin inhibits breast cancer development and progression in vitro and in vivo by suppressing notch signaling and regulating miRNAs. Cell Physiol Biochem. 37:1693–1711. 2015. View Article : Google Scholar : PubMed/NCBI

38 

Sato Y, Sasaki N, Saito M, Endo N, Kugawa F and Ueno A: Luteolin attenuates doxorubicin-induced cytotoxicity to MCF-7 human breast cancer cells. Biol Pharm Bull. 38:703–709. 2015. View Article : Google Scholar : PubMed/NCBI

39 

Sui JQ, Xie KP and Xie MJ: Inhibitory effect of luteolin on the proliferation of human breast cancer cell lines induced by epidermal growth factor. Sheng Li Xue Bao. 68:27–34. 2016.PubMed/NCBI

40 

Mizushima N and Komatsu M: Autophagy: Renovation of cells and tissues. Cell. 147:728–741. 2011. View Article : Google Scholar : PubMed/NCBI

41 

Quan W, Jung HS and Lee MS: Role of autophagy in the progression from obesity to diabetes and in the control of energy balance. Arch Pharm Res. 36:223–229. 2013. View Article : Google Scholar : PubMed/NCBI

42 

Szczesny B, Brunyánszki A, Ahmad A, Oláh G, Porter C, Toliver-Kinsky T, Sidossis L, Herndon DN and Szabo C: Time-dependent and organ-specific changes in mitochondrial function, mitochondrial DNA integrity, oxidative stress and mononuclear cell infiltration in a mouse model of burn injury. PLoS One. 10:e01437302015. View Article : Google Scholar : PubMed/NCBI

43 

Li X, Xu HL, Liu YX, An N, Zhao S and Bao JK: Autophagy modulation as a target for anticancer drug discovery. Acta Pharmacol Sin. 34:612–624. 2013. View Article : Google Scholar : PubMed/NCBI

44 

Lamy L, Ngo VN, Emre NC, Shaffer AL III, Yang Y, Tian E, Nair V, Kruhlak MJ, Zingone A, Landgren O, et al: Control of autophagic cell death by caspase-10 in multiple myeloma. Cancer Cell. 23:435–449. 2013. View Article : Google Scholar : PubMed/NCBI

45 

Luo YH, Wu SB, Wei YH, Chen YC, Tsai MH, Ho CC, Lin SY, Yang CS and Lin P: Cadmium-based quantum dot induced autophagy formation for cell survival via oxidative stress. Chem Res Toxicol. 26:662–673. 2013. View Article : Google Scholar : PubMed/NCBI

46 

Yamanaka T, Shiraki K, Sugimoto K, Ito T, Fujikawa K, Ito M, Takase K, Moriyama M, Nakano T and Suzuki A: Chemotherapeutic agents augment TRAIL-induced apoptosis in human hepatocellular carcinoma cell lines. Hepatology. 32:482–490. 2000. View Article : Google Scholar : PubMed/NCBI

47 

Shankar S and Srivastava RK: Enhancement of therapeutic potential of TRAIL by cancer chemotherapy and irradiation: mechanisms and clinical implications. Drug Resist Updat. 7:139–156. 2004. View Article : Google Scholar : PubMed/NCBI

48 

Chen JJ, Chou CW, Chang YF and Chen CC: Proteasome inhibitors enhance TRAIL-induced apoptosis through the intronic regulation of DR5: involvement of NF-kappa B and reactive oxygen species-mediated p53 activation. J Immunol. 180:8030–8039. 2008. View Article : Google Scholar : PubMed/NCBI

49 

Kim H, Kim EH, Eom YW, Kim WH, Kwon TK, Lee SJ and Choi KS: Sulforaphane sensitizes tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-resistant hepatoma cells to TRAIL-induced apoptosis through reactive oxygen species-mediated up-regulation of DR5. Cancer Res. 66:1740–1750. 2006. View Article : Google Scholar : PubMed/NCBI

50 

Jung EM, Lim JH, Lee TJ, Park JW, Choi KS and Kwon TK: Curcumin sensitizes tumor necrosis factor-related apop-tosis-inducing ligand (TRAIL)-induced apoptosis through reactive oxygen species-mediated upregulation of death receptor 5 (DR5). Carcinogenesis. 26:1905–1913. 2005. View Article : Google Scholar : PubMed/NCBI

51 

Horinaka M, Yoshida T, Shiraishi T, Nakata S, Wakada M and Sakai T: The dietary flavonoid apigenin sensitizes malignant tumor cells to tumor necrosis factor-related apoptosis-inducing ligand. Mol Cancer Ther. 5:945–951. 2006. View Article : Google Scholar : PubMed/NCBI

52 

Chen L, Meng Y, Guo X, Sheng X, Tai G, Zhang F, Cheng H and Zhou Y: Gefitinib enhances human colon cancer cells to TRAIL-induced apoptosis of via autophagy- and JNK-mediated death receptors upregulation. Apoptosis. 21:1291–1301. 2016. View Article : Google Scholar : PubMed/NCBI

53 

Cheng H, Hong B, Zhou L, Allen JE, Tai G, Humphreys R, Dicker DT, Liu YY and El-Deiry WS: Mitomycin C poten-tiates TRAIL-induced apoptosis through p53-independent upregulation of death receptors: Evidence for the role of c-Jun N-terminal kinase activation. Cell Cycle. 11:3312–3323. 2012. View Article : Google Scholar : PubMed/NCBI

54 

Thamkachy R, Kumar R, Rajasekharan KN and Sengupta S: ERK mediated upregulation of death receptor 5 overcomes the lack of p53 functionality in the diaminothiazole DAT1 induced apoptosis in colon cancer models: Efficiency of DAT1 in Ras-Raf mutated cells. Mol Cancer. 15:222016. View Article : Google Scholar : PubMed/NCBI

55 

Shoeb M, Ramana KV and Srivastava SK: Aldose reductase inhibition enhances TRAIL-induced human colon cancer cell apoptosis through AKT/FOXO3a-dependent upregulation of death receptors. Free Radic Biol Med. 63:280–290. 2013. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

February 2019
Volume 54 Issue 2

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Nazim, U.M., & Nazim, U.M. (2019). Luteolin sensitizes human liver cancer cells to TRAIL‑induced apoptosis via autophagy and JNK‑mediated death receptor 5 upregulation. International Journal of Oncology, 54, 665-672. https://doi.org/10.3892/ijo.2018.4633
MLA
Nazim, U. M., Park, S."Luteolin sensitizes human liver cancer cells to TRAIL‑induced apoptosis via autophagy and JNK‑mediated death receptor 5 upregulation". International Journal of Oncology 54.2 (2019): 665-672.
Chicago
Nazim, U. M., Park, S."Luteolin sensitizes human liver cancer cells to TRAIL‑induced apoptosis via autophagy and JNK‑mediated death receptor 5 upregulation". International Journal of Oncology 54, no. 2 (2019): 665-672. https://doi.org/10.3892/ijo.2018.4633